The US FDA has shown a willingness to license biosimilars with container closure systems or delivery devices that differ from the reference biologic, but interchangeability determinations may be harder to come by for such products.
FDA’s recently released draft guidance on interchangeability considerations discusses how differences in product presentation between a biosimilar and...